Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pyrotinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer:a Randomised, Double-blind, Multicentre, Phase 3 Trial

Next Previous
X
Search
Trial Profile

Pyrotinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer:a Randomised, Double-blind, Multicentre, Phase 3 Trial

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pyrotinib (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PHENIX
  • Sponsors Jiangsu Hengrui Medicine Co.

    • Most Recent Events

    • 24 Oct 2022 Planned End Date changed from 1 Dec 2019 to 1 Jun 2023.
    • 24 Oct 2022 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2023.
    • 31 May 2020 Results (N=63), pooled analysis of three trials, assessing efficacy of pyrotinib plus capecitabine pts with HER2-positive, trastuzumab-resistant relapsed or metastatic breast cancer, presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top